Journal: Translational Oncology
Article Title: Tumor-stroma contributes to immunotherapeutic resistance in non-small cell lung cancer via SEMA3C-mediated immunosuppressive tumor microenvironment
doi: 10.1016/j.tranon.2026.102679
Figure Lengend Snippet: SEMA3C-targeting treatment inhibited tumor growth and restored T cell function. (A) Schematic of the treatment protocol in mice bearing Lewis cells. (B) Tumor growth curve of mice treated with PBS and the SEMA3C-targeting treatment. (C-D) Representative images showing the tumors harvested from mice bearing Lewis cells treated with PBS and the SEMA3C-targeting treatment, and weight of the harvested tumors. Data was presented as mean±SD. Significance was calculated with the Student’s t -test. **** P < 0.001. (E-G) Relative concentrations of PD-1 (E), GZMB (F), and IFN-γ (G) as measured by ELISA in Lewis cell-bearing mice treated with PBS or SEMA3C-targeting treatment. Data was presented as mean±SD. Significance was calculated with the Student’s t -test. * P < 0.05, ** P < 0.01.
Article Snippet: Additionally, mouse protein levels of programmed death-1 (PD-1, catalog EK2271), IFN-γ (catalog EK280), and granzyme B (GZMB, catalog EK2173) in peripheral blood from Lewis lung carcinoma-bearing mice were assessed using ELISA kits from MultiSciences (LIANKE) Biotech Co., Ltd (Hangzhou, China).
Techniques: Cell Function Assay, Enzyme-linked Immunosorbent Assay